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Abstract: Microbes typically exist in mixed communities and display complex synergistic and
antagonistic interactions. The Type VI secretion system (T6SS) is widespread in Gram-negative
bacteria and represents a contractile nano-machine that can fire effector proteins directly into
neighbouring cells. The primary role assigned to the T6SS is to function as a potent weapon during
inter-bacterial competition, delivering antibacterial effectors into rival bacterial cells. However, it has
recently emerged that the T6SS can also be used as a powerful weapon against fungal competitors,
and the first fungal-specific T6SS effector proteins, Tfe1 and Tfe2, have been identified. These effectors
act via distinct mechanisms against a variety of fungal species to cause cell death. Tfe1 intoxication
triggers plasma membrane depolarisation, whilst Tfe2 disrupts nutrient uptake and induces autophagy.
Based on the frequent coexistence of bacteria and fungi in microbial communities, we propose that
T6SS-dependent antifungal activity is likely to be widespread and elicited by a suite of antifungal
effectors. Supporting this hypothesis, homologues of Tfe1 and Tfe2 are found in other bacterial
species, and a number of T6SS-elaborating species have been demonstrated to interact with fungi.
Thus, we envisage that antifungal T6SS will shape many polymicrobial communities, including the
human microbiota and disease-causing infections.
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1. Introduction
Bacteria and fungi are ubiquitous in nature and co-colonise numerous environmental niches.
Focussing on the human host, such cross-kingdom interactions are prevalent within the human microbiota,
and are commonly associated with biofilms and medically relevant infections [1]. Such interactions may
be chemical, physical or occur through alteration of the shared environmental niche, and, importantly,
can be synergistic or antagonistic for the species involved. Regarding synergistic interactions, there are
several examples of how bacterial and fungal co-infection potentiates host colonisation and virulence [2–4],
and mixed species biofilms have been shown to create protective environments [5,6]. Conversely,
several Gram-negative pathogens, including Salmonella enterica serovar Typhimurium [7], Pseudomonas
aeruginosa [8], and the emerging pathogen Acinetobacter baumannii [9], secrete molecules that can kill
fungal cells. Perhaps the best characterised is P. aeruginosa and its interactions with an important fungal
pathogen of humans, Candida albicans. P. aeruginosa preferentially binds to and forms biofilms on hyphal C.
albicans cells and kills the fungus through the action of two virulence factors, secreted phospholipase C
and redox-active phenazines [8]. P. aeruginosa also produces a quorum signalling molecule which inhibits
the yeast to hyphal switch [10], an important virulence trait in C. albicans.
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Whilst antagonistic bacterial-fungal interactions are well recognised, the discovery that a bacterium
can directly inject antifungal effectors into fungal cells opens up an exciting new research area underpinning
polymicrobial interactions. Recently, we reported that the “antibacterial” Type VI secretion system (T6SS)
within the opportunistic pathogen Serratia marcescens, is also a potent antifungal weapon [11]. Two
dedicated antifungal effectors, Tfe1 and Tfe2, are translocated into fungal cells by the S. marcescens T6SS,
ultimately resulting in fungal death [11]. Here we give an overview of the T6SS and mechanism of effector
delivery before focussing on the identification and mode of action of the newly discovered Tfe1 and Tfe2
antifungal effectors. We also present evidence that T6SS-dependent antifungal activity is likely to be a
widespread determinant of microbial community composition, before finishing with the key questions
and opportunities for future research afforded by this exciting new area of biology.
2. Occurrence of Type VI Secretion Systems
The T6SS is a bacterial nano-weapon that can be used to translocate toxic effector proteins directly
into neighbouring cells. It is a versatile system that can be used to deliver antibacterial toxins into
rival bacterial cells, representing an important means of inter-bacterial competition, but can also
be used to deliver effectors which damage or manipulate host cells, representing direct virulence
factors [12]. T6SSs are widely distributed in Gram-negative bacteria. It has been estimated that at
least 25% of Gram-negative bacteria contain at least one T6SS, most commonly within the α, β and
γ-proteobacteria [13,14]. The majority of such ‘classical’ T6SSs appear to have antibacterial activity,
whilst some also, or exclusively, possess anti-host activities. More recently, it has become clear
that several other distantly-related families of T6SS also exist, sharing a basic mechanism but with
differences in the core machinery. One of these divergent T6SSs occurs in the Bacteroidetes, a Phylum
including key members of the gut microbiota, and is used for inter-bacterial competition [15,16].
Bacterial species, and indeed individual strains within a species, vary greatly in their complement
of T6SSs, from none up to six different T6SSs, whilst the complement of secreted effector proteins
is even more variable [12]. In some cases, the same T6SS can be used for two different functions,
such as the Vibrio cholerae T6SS which is used against both competitor bacteria and the host [17].
In other cases, different T6SSs fulfil distinct roles, for example in Burkholderia thailandensis, where
T6SS-1 is reported to be exclusively antibacterial, T6SS-5 appears to be exclusively anti-host and T6SS-4
has a distinct role in delivering a manganese-scavenging metallophore protein to the extracellular
milieuwhere [18,19]. Regarding potential roles for T6SSs in mediating bacterial-fungal interactions,
it is noteworthy that many bacterial species which co-exist with fungi possess T6SSs. Considering
bacterial species involved in medically-relevant bacterial-fungal interactions, P. aeruginosa, A. baumannii,
S. Typhimurium, Escherichia coli and Burkholderia cenocepacia, possess well-characterised T6SSs [20–24].
Similarly, many plant-associated bacteria, including plant growth promoting Rhizobia, biocontrol
organisms such as Pseudomonas fluorescens and Pseudomonas putida, and plant pathogens including
Agrobacterium tumefaciens and Pectobacterium species, contain T6SSs [25].
3. Effector Delivery by the Type VI Secretion System
The T6SS is a large, multiprotein machinery anchored in the inner and outer bacterial membranes.
It uses a contraction-based mechanism to propel an arrow-like puncturing device decorated with
multiple effector proteins out of the bacterial cell and into neighbouring target cells. In this way, effectors
are delivered inside the targeted cell, from where they exert their toxic activities [12]. The mechanism
of this machinery, which is related to that of contractile bacteriophage tails, has been reviewed
extensively [26–29] and the current model will be summarised here (Figure 1). The expelled puncturing
device comprises a tube made of stacked rings of the Hcp protein, tipped with a sharp spike made of
a trimer of VgrG proteins and one PAAR protein. To achieve “firing” of this structure, a membrane
complex is assembled across both bacterial membranes, which then serves as a docking site for the
cytoplasmic baseplate complex, within which sits the VgrG-PAAR spike. The Hcp tube can then be
assembled onto the spike, extending out across the bacterial cytoplasm. A sheath-like structure made
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up of the TssBC proteins simultaneously assembles around the Hcp tube in an extended, high-energy
conformation, with the two structures linked by a “cap” at the distal end. A rapid and powerful sheath
contraction event then drives the Hcp-VgrG-PAAR structure through the baseplate and membrane
complex, out of the bacterial cell and into a suitably positioned recipient cell, followed by effector
release inside the targeted cell. The contracted sheath is disassembled by a dedicated ATPase, TssH,
and further rounds of T6SS assembly and firing can occur.
J. Fungi 2019, 5, x FOR PEER REVIEW 3 of 13 
 
in an extended, high-energy conformation, with the two structures linked by a “cap” at the distal 
end. A rapid and powerful sheath contraction event then drives the Hcp-VgrG-PAAR structure 
through t  baseplate and membrane c mplex, out of the bacterial cell and into a suitably positioned 
recipient cell, followed by effector release inside the targeted cell. The contracted sheath is 
disassembled by a dedicated ATPase, TssH, and further rounds of T6SS assembly and firing can 
occur.  
 
Figure 1. Type VI secretion system-mediated delivery of antifungal effector proteins between Serratia 
marcescens and fungal cells. Schematic representation of the current models for effector delivery by 
the bacterial Type VI secretion system (T6SS) and the impact of the antifungal effector proteins Tfe1 
and Tfe2 on cells of Candida albicans, Candida glabrata and Saccharomyces cerevisiae. In the secreting 
bacterial cell, contraction of the TssBC sheath propels a cell puncturing structure, decorated with 
effector proteins, through the membrane-anchored basal complex, out of the bacterial cell and into an 
adjacent target cell. The cell puncturing structure comprises a tube made of Hcp proteins and a spike 
made of VgrG and PAAR proteins. Effectors can bind in the lumen of the Hcp tube, as for Tfe1 and 
Tfe2, or to the outside of the spike (not shown), or they can be present as additional domains fused to 
spike proteins (example shown in black although antifungal effectors of this kind have yet to be 
described). Following breach of the target cell due to the mechanical force of the contraction event, 
effectors are somehow released in the target cell and induce toxicity by distinct mechanisms. In the 
case of the antifungal effectors, Tfe1 and Tfe2, intoxication leads to plasma membrane depolarisation 
Figure 1. Type VI secretion system-mediated deli ry of antifungal effector proteins b tween Serratia
marcescens and fungal cells. Schematic representation of t e c rrent models for effector delivery by the
bacterial Type VI secretion system (T6SS) and the impact of the antifungal effector proteins Tfe1 and
Tfe2 on cells of Candida albicans, Candida glabrata and Saccharomyces cerevisiae. In the secreting bacterial
cell, contraction of the TssBC s eath propels a cell puncturing structure, decorated with effector proteins,
through the membrane-anchored basal complex, out of the bacterial cell and into an adjacent target
cell. The cell puncturing structure comprises a tube made of Hcp proteins and a spike made of VgrG
and PAAR proteins. Effectors can bind in the lumen of the Hcp tube, as for Tfe1 and Tfe2, or to the
outside of the spike (not shown), or they can be present as additional domains fused to spike proteins
(example shown in black although antifungal ff ctors of this kind have yet o be de cribed). Following
breach of the target cell due to the mechanical force of the contraction event, effectors are somehow
released in the target cell and induce toxicity by distinct mechanisms. In the case of the antifungal
effectors, Tfe1 and Tfe2, intoxication leads to plasma membrane depolarisation for Tfe1, whilst it leads
to a disruption of nutrient uptake and amino acid metabolism, leading to starvation response and
induction of autophagy for Tfe2. Note that the Serratia marcescens T6SS also delivers eight antibacterial
effector proteins which cause efficient killing of bacterial competitors (not shown).
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In order to achieve effector delivery, effectors associate with the Hcp-VgrG-PAAR structure in a
number of ways [12]. They can interact non-covalently with the inside of the Hcp tube or with the
outside of the VgrG-PAAR spike. Alternatively, VgrG, Hcp and PAAR proteins may possess additional
effector-containing domains, normally at their C-termini. To accommodate multiple different effector
proteins, T6SSs typically contain multiple copies of Hcp, VgrG and/or PAAR proteins and often possess
effector-specific chaperones to aid loading of the effector onto the machinery. The T6SS appears to be a
very flexible delivery machine, able to deliver effectors of a variety of sizes, structures and functions.
These range from antibacterial effectors with cell wall hydrolase, phospholipase and nuclease activities,
through metal scavenging proteins, to anti-host effectors with actin modification, inflammasome
modulation and membrane fusion functions [12,30,31].
4. Identification of T6SS Antifungal Effectors
The first indications that the T6SS may play a role in bacterial-fungal interactions were reported
for plant-associated bacteria, which frequently share their habitat with symbiotic or disease-causing
fungi [32,33]. More specifically, the plant-associated Pseudomonad, P. fluorescens Pf29Arp, which
has been shown to protect wheat roots from the pathogenic fungus Gaeumannomyces graminis var.
tritici, exhibited increased expression of T6SS genes if cultured on fungus-infected roots compared
with healthy roots [33,34]. In addition, direct T6SS-dependent activity against both bacterial and
fungal competitors was reported for the pathogenic phytobacterium Pseudomonas syringae pv. tomato
DC3000 [35]. However, in both cases, no antifungal T6SS effectors were identified. In contrast,
effector-based antifungal activity was reported for the T6-secreted protein Tse2 of P. aeruginosa when
overexpressed ectopically in the model yeast S. cerevisiae [36,37]. Similarly, transfection of HeLa cells
with Tse2 led to cell-rounding. However in physiologically more relevant co-culture experiments,
when Tse2 would be delivered by the T6SS, Tse2 toxicity was restricted only to other bacteria [37].
Subsequent structural analysis of Tse2 revealed identity with ADP-ribosyltransferase toxins [38],
suggesting general cytotoxic activity towards an evolutionary conserved target rather than being an
effector deployed against fungal cells.
Identification of the first fungal-specific T6-secreted effectors was recently reported for the model
strain, Serratia marcescens Db10 [11]. S. marcescens possesses a single potent antibacterial T6SS, which
has been shown to deliver at least eight distinct antibacterial effectors, and is post-translationally
regulated to fire in an offensive manner [39]. Co-culturing S. marcescens with the model yeast S.
cerevisiae, or the opportunistic pathogenic fungi C. albicans and C. glabrata, resulted in T6SS-dependent
inhibition of fungal growth. This effect was dependent on cell-to-cell contact, dispelling doubts about
whether the T6SS could breach the thick and rigid fungal cell wall.
To identify the effectors responsible for antifungal activity, initial experiments focussed on
T6-secreted proteins which had previously been identified in a proteomics screen comparing the
secretome of wild type S. marcescens with that of a T6SS-inactive mutant [40]. Of these, only one,
Ssp3, exhibited fungicidal activity against C. albicans. Interestingly, Ssp3 was initially classified as an
antibacterial toxin, since overexpression in E. coli produced modest toxicity, which was alleviated upon
co-expression of a small open reading frame situated directly upstream of the toxin [40]. However,
deletion of this immunity gene, sip3, in S. marcescens did not affect viability, and no inhibition of
the ∆sip3 mutant upon co-culture with strains able to perform T6SS-mediated delivery of Ssp3 was
observed, indicating that Ssp3 is not an antibacterial effector under such conditions [11]. This is in
contrast with true T6SS antibacterial effectors, where mutants lacking the cognate immunity protein
are non-viable due to self-killing and are susceptible to delivery of the cognate effector upon co-culture
with a wild type strain. To reflect its antifungal rather than antibacterial activity and its identification
as the first T6SS-secreted antifungal effector protein, Ssp3 was renamed Tfe1. However, deletion of
tfe1 in S. marcescens did not reduce antifungal activity against S. cerevisiae or C. glabrata in co-culture
experiments, suggesting the existence of additional antifungal effectors. To identify such effectors, a
second proteomics approach was employed to capture the cellular proteome, rather than the secretome,
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with the rationale that a T6SS-inactive mutant would retain potential effector proteins inside the cell.
Analysis of the cellular proteome of a ∆tssE mutant compared with wild type S. marcescens revealed
twelve proteins that displayed increased abundance in the T6SS-inactive mutant. Nine were proteins
already known to be secreted by the T6SS, including components of the puncturing structure and
Tfe1, whilst the remaining three proteins were unlikely to be antibacterial effectors since they were not
encoded next to potential cognate immunity proteins. Subsequently, mutational analysis identified
one of these three candidates as the second antifungal effector, Tfe2 [11]. Notably, whilst Tfe2 failed to
exhibit antibacterial activity, loss of Tfe2 virtually abolished S. marcescens antifungal activity against S.
cerevisiae and C. glabrata. Thus the “antibacterial” S. marcescens T6SS is also a potent antifungal weapon,
able to kill S. cerevisiae and Candida spp. by delivering two dedicated antifungal effectors Tfe1 and Tfe2.
Given rapid recent advances in the T6SS field, relating to both its structure and secretion
mechanism [41–44] and the diversity of secreted proteins [12], it is perhaps surprising that
antifungal-specific effectors have been identified only recently [11]. This is likely due to the fact that the
strategies used to discover novel effectors have been based on the assumption that T6SSs are primarily
employed as weapons in interbacterial warfare or else as classical virulence factors against higher
eukaryotes. Therefore, effector identification strategies have often relied on their presumed antibacterial
activity and the presence of cognate immunity proteins. For example, using unbiased proteomics
approaches, only those T6-secreted proteins harbouring a potential immunity protein were considered
candidate T6SS effector proteins, with confirmation being based on their ability to kill a non-immune
sibling strain [37,40]. Similarly, effector identification via random transposon mutagenesis and deep
sequencing (Tn-seq) in wild type and T6SS inactive mutant backgrounds relied on the identification of
immunity proteins as being essential in the presence of a functional T6SS [45]. However, by using such
strategies antifungal effectors would be missed. Indeed, no immunity protein is associated with Tfe2,
consistent with the premise that bacteria deploying fungal-specific toxins would not require cognate
immunity proteins for protection. Furthermore, hypothesis-driven in silico discovery of T6SS effectors,
based on domain and homology screens (e.g., peptidoglycan-degrading enzymes [46], lipases [47] and
MIX-motif containing proteins [48]), are led by the prior knowledge of previously identified effectors
and thus are likely to miss novel fungal-specific effector proteins. Alternatively, effectors are often
located within T6SS gene clusters or distant loci encoding additional Hcp, VgrG and/or PAAR proteins,
and so candidate effectors can be identified by their genetic context. Similarly, candidate effector
domains fused with VgrG or PAAR proteins are readily identifiable through bioinformatic analysis.
However, these approaches will miss effectors located in genomic regions otherwise unrelated to T6SS,
such as Tfe1 and Tfe2, and to-date have again typically relied on identification of immunity proteins
and/or demonstration of antibacterial activity as validation as bona fide T6SS substrates.
It is also important to note that antifungal effectors (like antibacterial or anti-host effectors) may
be delivered by T6SSs that are silent under laboratory conditions, thus hindering their identification.
Knowledge about signalling pathways and regulatory mechanisms, in combination with genetic tools
to generate constitutively active T6SSs, may prove instrumental in the discovery of future T6SS effectors.
This has been exemplified by deletion of the gene encoding for the sensor kinase RetS in P. aeruginosa or
the quorum-sensing master regulator OpaR in V. parahaemolyticus, both rendering the respective T6SSs
constitutively active [49,50]. Similarly, interfering with the phosphorylation status of the scaffolding
protein Fha1 by deleting the Ser-Thr phosphatase PppA in P. aeruginosa locks the T6SS in its active state,
which allowed for identification of T6-secreted proteins under standard laboratory conditions [51].
Future strategies to study such silent T6SSs will likely require a combination of genetics tools together
with performing co-culture experiments under physiologically relevant conditions. In this regard it
is notable that the laboratory silent T6SSs of V. cholerae O1 serogroup strains C6706 and N16961 are
stimulated by intestinal factors, namely, mucins and bile salts [52].
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5. Mode of Action of Tfe1 and Tfe2
Tfe1 and Tfe2 are small proteins comprising 183 and 226 amino acids with predicted molecular
masses of 20 and 26 kDa, respectively. No discernible conserved domains or predicted functions could
be identified for either protein, using standard bioinformatics tools. Once inside the fungal cell, Tfe1
and Tfe2 trigger distinct morphological responses, with Tfe1 causing cell distortion and lysis and Tfe2
giving rise to granular structures [11].
Using the voltage-dependent dye DiBAC4(3), which can only enter depolarised cells, Tfe1 was
found to trigger a loss of plasma membrane potential [11]. Only a small fraction of Tfe1-intoxicated
cells co-stained with propidium iodide (PI), an indicator for loss of membrane integrity. This indicates
that Tfe1 causes loss of plasma membrane potential without forming pores, similar to the action of the
membrane depolarising antifungal drug amphotericin B, but in contrast to the pore-forming peptide
mellitin. This effect was seen upon direct co-culture of C. albicans with wild-type S. marcescens but not
the ∆tfe1 mutant, as well as upon ectopic expression of Tfe1 in S. cerevisiae, suggesting Tfe1 is targeting
a conserved fungal pathway. Interestingly, although the fungicidal action of Tfe1 was confirmed by
decreased survival rates of C. albicans in co-culture settings, both S. cerevisiae and C. glabrata are much
more resistant to Tfe1 action. As the latter are phylogenetically more closely related to each other than
to C. albicans, the observed species specificity of Tfe1 might be related to a divergence in the targeted
pathway between those two clades.
The precise mechanism of Tfe1-elicited membrane depolarisation is unknown. In S. cerevisiae,
membrane potential is controlled mainly by the regulation of proton and potassium cation fluxes,
with the main regulator being the extensively studied and well-characterised Pma1 H+-ATPase [53].
This protein pumps protons out of the cytosol to regulate intracellular pH and creates a proton
electrochemical gradient across the plasma membrane. If Tfe1 functions to inhibit Pma1, this would
block H+ efflux from the cell resulting in loss of membrane potential, as has been recently reported for
several antifungal compounds acting on Pma1 [54]. Alternatively, Tfe1 may impact on the activity of
K+ transporters to trigger membrane depolarisation [55], or via a mechanism akin to the antifungal
amphotericin B or, indeed, via a novel mechanism.
The second antifungal effector, Tfe2, was the most potent toxin against S. cerevisiae and C. glabrata,
whilst displaying approximately equal activity as Tfe1 against C. albicans [11]. Whilst PI staining of C.
glabrata co-cultured with S. marcescens suggested Tfe2-dependent killing of the fungus, Tfe2-intoxication
of both S. cerevisiae and C. albicans was fungistatic, with reduced long-term survival. These data
suggest that Tfe2 targets a conserved pathway, but with distinct fungi exhibiting varying levels of
susceptibility. To determine the impact of Tfe2 intoxication, an “in competition” proteomics experiment
was performed to identify C. albicans proteins differentially affected upon co-culture of C. albicans
with wild type S. marcescens compared to co-culture with mutants of S. marcescens unable to deliver
Tfe2 [11]. This revealed a Tfe2-dependent reduction in nutrient transporters, including the sole
sulphate transporter Sul2, and the amino acid permeases Gap1, Gap2, Can1 and Can2. Moreover,
the entire sulphate assimilation pathway was downregulated upon Tfe2 intoxication. In contrast,
Tfe2 intoxication stimulated increased levels of the Gcn4 transcriptional activator which mediates
the general amino acid control (GAAC) response following amino acid starvation [56,57], and the
autophagy-activating Ser/Thr kinase Atg1, which is subject to regulation by the nutrient-sensing TOR
signalling pathway [58]. These data strongly suggested interference of Tfe2 with nutrient sensing or
uptake pathways. Although no direct target was identified, certain hypotheses were considered. First,
decrease in transporter levels could occur via transcriptional downregulation. However, increased
transcript abundance of transporters or their transcriptional regulators was observed upon exposure
to Tfe2, likely as a compensatory mechanism. Alternatively, Tfe2-mediated decrease in transport
proteins could be triggered by nutrient-binding induced endocytosis, but the probability of this
scenario is low due to invariant media composition. Perhaps Tfe2 functions to interfere with protein
synthesis or vesicle trafficking/premature vacuolar targeting which could underlie the decrease in
nutrient transporters, which in turn would elicit nutrient starvation response pathways. Whatever the
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mechanism, Tfe2-mediated depletion of nutrient transporters at the post-transcriptional level leads to
amino acid imbalance resulting in induction of autophagy. Which, if any, of these Tfe2-dependent
effects is responsible for fungal death remains to be determined. However, it is noteworthy that deletion
of the basic amino acid transporter Can1 and its paralog Alp1, which are down-regulated by Tfe2, give
a lethal phenotype in S. cerevisiae [59]. In addition, Tfe2 increases levels of the Gcn4 transcriptional
activator, and previous studies have revealed that Gcn4 over-expression stunts growth [60].
The S. marcescens T6SS, and by implication Tfe1 and Tfe2, do not appear to act against higher
eukaryotic cells as strains lacking a functional T6SS show no loss of virulence [11,39]. Furthermore, Tfe1
and Tfe2, which trigger plasma membrane depolarisation and impaired nutrient uptake, respectively,
seemingly display a different mode-of action to T6SS-delivered anti-host effectors reported to date.
Such anti-host effectors target diverse processes encountered by pathogens during infection to allow
immune evasion [30]. Several manipulate the host cytoskeleton, via the generation of toxic actin
oligomers in V. cholerae V52 [61], by inhibiting F-actin formation in A. hydrophila [62], or by activation
of the Pyrin inflammasome via Rho GTPase deaminase activity in B. cenocepacia [63]. Other anti-host
effectors include those able to modulate microtubule-mediated bacterial internalisation by binding to
tubulin or Akt, those able to promote phagosomal escape through PI(3)-kinase or membrane fusion
activities, and those able to counter inflammasome activation or host ROS, as reviewed in [12]. Based
on the recent findings that the T6SS can target fungal competitors [11], it will be interesting to ask
whether previously designated anti-host effectors are also active against fungal cells.
6. Prevalence of T6SS-Dependent Antifungal Activity
Due to the frequent co-existence of T6SS-containing bacteria and fungi in microbial communities,
it is likely that T6SS-mediated antifungal activity is widespread. For example, multiple T6SSs are
prevalent among major constituents of the gut microbiota, the Bacteroidetes [64], which comprise
approximately half of the colonic bacteria within the human population. Furthermore, 73% of 143
analysed plant-associated bacteria of the Proteobacterium phylum possess at least 1 and up to 5 distinct
T6SS clusters [25]. Such T6SS-containing plant and human associated bacteria are intimately associated
with fungi, supporting the concept that T6SS antifungal activity is not restricted to S. marcescens.
Indeed, our analysis has revealed that Tfe1 and Tfe2 homologues are found in a number of bacterial
species. Conducting neighbour-joining tree analyses of Tfe1 and Tfe2 using the non-redundant
sequence database of NCBI depicted that both effectors were restricted to Gram-negative bacteria
but not exclusive to the S. marcescens clade (Figure 2). Indeed, homologues are present in a variety
of proteobacteria, including closely related Enterobacterales, but also more distantly related species
like Burkholderiales, Pseudomonadales and Vibrionales, representing both human and plant-associated
pathogens and environmental strains. All species possessing a Tfe1 or Tfe2 homologue also contain at
least a potential vgrG gene in their genome which is indicative of a functional T6SS. However, whether
all strains within a particular species contain Tfe1 or Tfe2, and the genes necessary for an active T6SS
machinery, requires further analysis. We also posit that Tfe1 and Tfe2 will be representatives of an
array of novel T6-secreted antifungal effectors. In this regard it is relevant that Tfe1 and Tfe2 are not
present in the plant associated strains P. fluorescens Pf29Arp and P. syringae pv. tomato DC3000, in
which anti-fungal T6SS activity was first described [33–35]. Furthermore, as detailed above, antifungal
effectors may have been missed in many other studies due to the standard identification criteria being
based on antibacterial activity (which Tfe1 and Tfe2 do not display). These include proteins omitted
due to the lack of antibacterial activity upon deletion of the respective cognate immunity protein, or
the absence altogether of potential immunity candidates (e.g., VP1390 in V. haemolyticus [48]).
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7. Roles for Antifungal T6SSs in Polymicrobial Communities?
The majority of studies on antibacterial T6SSs have concentrated on in vitro competition
experiments which has driven the rapid advancement of our molecular understanding of the T6SS.
Although fruitful, such approaches give limited insight into the functionality of T6SSs in natural
polymicrobial communities. However, recent studies have revealed that a range of bacteria utilise
their T6SS to confer a competitive advantage within the polymicrobial community of the gut. This was
demonstrated in S. Typhimurium where the T6SS encoded within Salmonella pathogenicity island 6
was shown to promote successful colonisation of the mouse gut [22]. Similarly, Shigella sonnei, but not
Shigella flexneri, contains a T6SS that allows it to outcompete S. flexneri and E. coli in the mouse gut, and
it is suggested that this T6SS-conferred competitive advantage may contribute to the global rise in
S. sonnei incidence [65]. The V. cholerae T6SS not only antagonises commensal E. coli species, but also
functions to enhance the virulence of this enteric pathogen [66]. Specifically, T6SS-mediated killing of
E. coli commensals both stimulated V. cholerae virulence gene expression and intensified innate immune
responses [66]. In addition to these enteric pathogens, T6SS are employed by Bacteroidales species.
Three different genetic architectures (GA) of T6SS are prevalent; GA1 and GA2 are located on mobile
genetic elements and are readily transferred and shared amongst numerous Bacteroidales spp, whereas
GA3 is restricted to Bacteroides fragilis [64]. B. fragilis utilises its GA3 T6SS to antagonise human gut
Bacteroidales species, providing a competitive advantage in murine co-colonisation experiments [67].
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S. marcescens, which has a potent antifungal T6SS, is emerging as an important opportunistic
pathogen [68], and co-colonisation of this bacterium with commensal Candida species in dysbiotic
human gut communities has been reported [69]. In addition, co-infection experiments with other
medically-relevant, T6SS yielding, bacterial species including A. baumannii and S. Typhimurium have
been shown to decrease C. albicans virulence in the intestine of the model invertebrate host Caenorhabditis
elegans [7,9]. Collectively, these findings support the concept that antifungal T6SS may play a vital
role in modulating the fungal component of the gut microbiota. This may have medical relevance, as
growing evidence indicates that the mycobiota, like the bacterial microbiota, plays important roles in
immune homeostasis and health [70].
8. Outstanding Questions
The recent discovery that bacteria can use the T6SS to interact with fungal cells raises many
exciting questions and opportunities for future research. Given the ubiquitous nature of bacterial
and fungal cells, and their frequent co-occurrence in polymicrobial communities, we speculate that
T6SS-mediated bacterial-fungal interactions will turn out to be important in a multitude of biological
contexts. However the extent, mechanisms and importance of these interactions remains to be
established; with key questions including:
• How many bacteria with T6SSs can use these systems against fungal cells? It will also be interesting
to see if T6SSs dedicated to antifungal activity exist, perhaps regulated in response to fungal cues,
or if antifungal and antibacterial activity always co-occurs.
• How broad is fungal susceptibility to T6SS action? It remains to be seen whether other species,
genera and phyla can be targeted by bacterial T6SSs and whether particular T6SSs and/or effector
proteins are specific for different types of fungi. For example, it is unknown if true filamentous
fungi are susceptible to T6SS action. It is tempting to speculate that the composition of the fungal
cell wall may play a critical role in determining the efficacy of T6SS attacks.
• What are the precise modes of action of Tfe1 and Tfe2, and yet-to-be-identified T6SS antifungal
effectors, and how many toxin molecules are required to cause fungal death? It will be very
interesting to discover the range of activities such effectors might have and to determine whether
any effectors that act against fungal cells also act against higher eukaryotic host organisms. Indeed
we speculate that some of the effectors reported to act against host cells might have originally
been acquired to act against fungal competitors, as targets such as actin are conserved throughout
the eukaryotic kingdom.
• Can bacteria also use T6SSs to deliver effector proteins that promote positive, mutualistic
interactions between bacterial and fungal cells, rather than being solely antagonistic?
• What is the significance of T6SS-mediated bacterial-fungal interactions in “real-life” polymicrobial
communities? We look forward to learning how these interactions can change the balance
between health and disease, influence the gut microbiota or define the composition of
environmentally-important communities.
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